Most Popular
-
1
10-man S. Korea lose to Indonesia to miss out on Paris Olympic football qualification
-
2
Hybe-Ador feud should have limited effect on Hybe's overall performance: analysts
-
3
Second Gimpo civil servant found dead, after apologizing for not finishing work
-
4
DP leader says he will meet Yoon without conditions
-
5
First-ever meeting of president, opposition chief set to finally happen
-
6
NewJeans' singles, Japanese debut to proceed as planned, despite Hybe-Ador feud
-
7
Experts raise concerns about Japan putting pressure on Naver over Line
-
8
Samsung mobile chief, Google device head meet in Seoul
-
9
Blinken calls on China to press N. Korea to end its 'dangerous' behavior
-
10
Ship linked to NK arms shipments to Russia is moored in China: State Dept.
[THE INVESTOR] With Innotox, a liquid version of Botox, entering the third phase of clinical trials, analysts maintained “buy” ratings for the biopharmaceutical company, forecasting better performance in the second quarter.
As Allergan, a global leader that created Botox announced Aug. 9 that it will proceed to the next phase of trials for the injectable version of Botolinium toxin, developed and transferred by Medytox, “it is time to reevaluate it,” said Lee Seung-ho, an analyst at NH Investment & Securities.
As Allergan, a global leader that created Botox announced Aug. 9 that it will proceed to the next phase of trials for the injectable version of Botolinium toxin, developed and transferred by Medytox, “it is time to reevaluate it,” said Lee Seung-ho, an analyst at NH Investment & Securities.
The brokerage firm estimated the licensing to be worth 1.53 trillion won (US$1.40 billion), adding that the company also showed its strongest performance ever in the second quarter.
Eugene Investment’s Kwak Jin-hee agreed with the “buy” rating following the validation. “The value of Innotox, estimated to be worth 991 billion won, will gradually be reflected on that of the company. And the world market for Botolinium toxin and filler, another strength of Medytox, will show double digit growth by 2020,” she added.
By Hwang You-mee (glamazon@heraldcorp.com)
